CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $200.21M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 9.84: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.50%Below 5Y avg (1.78%)
Annual Rate
KRW 400.00Paid semi-annual
Payout Ratio
18.9%Sustainable
Payback Period
66.6 yr
Last Ex-Dividend
May 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
285.33BKRW200.21M · vs all stocks (USD)
Trailing P/E
5.33xRevenue (TTM)
110.99BKRW77.88M · vs all stocks (USD)
Profit Margin
8.17%Beta
0.3440xvs all stocks
52-Week Change
-51.36%vs all stocks
Forward Annual Dividend Yield
1.50%vs all stocks
Market Capitalization
285.33BKRW200.21M · vs all stocks (USD)
Enterprise Value
241.18BKRW169.22M · vs all stocks (USD)
Trailing P/E
5.33xForward P/E
6.56xPEG Ratio
-0.5299xPrice to Sales (TTM)
2.58xPrice to Book (MRQ)
0.9562xEnterprise to Revenue
2.17xEnterprise to EBITDA
8.53xGross Margin
44.65%Profit Margin
8.17%Operating Margin
15.38%Return on Assets (TTM)
5.10%Return on Equity (TTM)
7.26%Revenue (TTM)
110.99BKRW77.88M · vs all stocks (USD)
Revenue per Share (TTM)
11.80KKRWUpdated Jul 15, 2026Quarterly Revenue Growth
-13.10%Gross Profit (TTM)
44.07BKRW30.92M · vs all stocks (USD)
EBITDA (TTM)
55.43BKRW38.89M · vs all stocks (USD)
Net Income (TTM)
9.06BKRW6.36M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-87.90%Operating Cash Flow (TTM)
19.18BKRW13.46M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.62BKRW5.35M · vs all stocks (USD)
Forward Annual Dividend Rate
400.00KRWUpdated Jul 15, 2026Forward Annual Dividend Yield
1.50%vs all stocks
Trailing Annual Dividend Rate
400.00KRWUpdated Jul 15, 2026Trailing Annual Dividend Yield
1.50%vs all stocks
5-Year Average Dividend Yield
1.78%vs all stocks
Payout Ratio
18.87%Revenue
170.05BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
90.54BKRWFY2025 · Dec 31, 2025Gross Profit
79.52BKRWFY2025 · Dec 31, 2025Operating Income
42.33BKRW29.70M · vs all stocks (USD)
Pre-tax Income
63.82BKRWFY2025 · Dec 31, 2025Income Tax Expense
12.03BKRWFY2025 · Dec 31, 2025Net Income
51.79BKRWFY2025 · Dec 31, 2025EBIT
63.88BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
59.85BKRWFY2025 · Dec 31, 2025Research & Development
9.44BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
15.51BKRWFY2025 · Dec 31, 2025Other Operating Expenses
420.66MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
4.16BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
59.49MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
51.79BKRWFY2025 · Dec 31, 2025Operating Cash Flow
43.26BKRWFY2025 · Dec 31, 2025Free Cash Flow
35.33BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
39.88BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
51.79BKRWFY2025 · Dec 31, 2025Stock-based Compensation
405.11MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-4.10BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-9.01BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.18BKRWFY2025 · Dec 31, 2025Capital Expenditures
-7.94BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-76.02MKRWFY2025 · Dec 31, 2025Net Acquisitions
5.98BKRWFY2025 · Dec 31, 2025Purchase of Investments
-134.73BKRWFY2025 · Dec 31, 2025Sale of Investments
37.08BKRWFY2025 · Dec 31, 2025Other Investing Activity
-645.70MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-100.26BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-5.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-10.83BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.42BKRWFY2025 · Dec 31, 2025Shares Outstanding
11.10MSharesUpdated Jul 15, 2026Float Shares
5.45MSharesUpdated Jul 15, 2026% Held by Insiders
37.47%vs all stocks
% Held by Institutions
10.40%vs all stocks
Total Cash (MRQ)
54.35BKRW38.14M · vs all stocks (USD)
Total Cash per Share (MRQ)
5.78KKRWUpdated Jul 15, 2026Total Debt (MRQ)
32.73BKRW22.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2306xCurrent Ratio (MRQ)
3.06xBook Value per Share (MRQ)
27.97KKRWUpdated Jul 15, 2026Total Assets
323.64BKRW227.08M · vs all stocks (USD)
Total Current Assets
179.24BKRWFY2025 · Dec 31, 2025Total Liabilities
24.05BKRWFY2025 · Dec 31, 2025Total Non-current Assets
144.40BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
3.45BKRWFY2025 · Dec 31, 2025Total Current Liabilities
20.60BKRWFY2025 · Dec 31, 2025Cash
39.88BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
39.88BKRWFY2025 · Dec 31, 2025Other Short-term Investments
85.03BKRWFY2025 · Dec 31, 2025Accounts Receivable
29.27BKRWFY2025 · Dec 31, 2025Inventory
21.39BKRWFY2025 · Dec 31, 2025Accounts Payable
4.80BKRWFY2025 · Dec 31, 2025Short-term Debt
1.23BKRWFY2025 · Dec 31, 2025Other Current Liabilities
247.39MKRWFY2025 · Dec 31, 2025Long-term Debt
132.45MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
-190.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
5.61BKRWFY2025 · Dec 31, 2025Retained Earnings
222.07BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
299.59BKRW210.21M · vs all stocks (USD)
Treasury Stock
4.59BKRWFY2025 · Dec 31, 202552-Week Low
23.80KKRWUpdated Jul 15, 202652-Week High
77.20KKRWUpdated Jul 15, 202652-Week Change
-51.36%vs all stocks
Beta
0.3440xvs all stocks
50-Day MA
29.05KKRWUpdated Jul 15, 2026200-Day MA
39.13KKRWUpdated Jul 15, 2026Avg 10-Day Volume
35.52KSharesUpdated Jul 15, 2026Avg 30-Day Volume
34.97KSharesUpdated Jul 15, 2026Diluted EPS (TTM)
5.01KKRWUpdated Jul 15, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 9.84: safe zoneNotable
Altman Z-Score: 9.84
High structural barrier to entryNotable
Barrier to Entry: 0.65
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $200.21M, lower than 95% of all stocks globallySignificant
Market cap (USD): 200,207,142.973Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sillajen Inc.
Tier 1ProductionApproval-Gated PipelineRule
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
RxSight Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hans Biomed Corp.
Tier 1ProductionApproval-Gated PipelineRule
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Kalekim Kimyevi Maddeler Sanayi ve Ticaret A.Ş.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth
Kpit Technologies Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth
Xiamen Amoytop Biotech Co., Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMulti-Year Revenue, Profit, And Income Growth